The Outlook article ‘The struggle to do no harm’ (Nature 552, S74–S75; 2017) mistakenly claimed that the biopharmaceutical firm Cellectis had not responded to requests for interview. A comment from the company is now included in the online version of the story.
- CORRECTION
The struggle to do no harm
Nature 554, 31 (2018)
doi: https://doi.org/10.1038/d41586-018-01423-5
